Dihydro-beta-ergocryptine methanesulfonate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 英文名称: Dihydro-beta-ergocryptine methanesulfonate
• 英文别名: (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-butan-2-yl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
• 化学式: C33H47N5O8S
• 分子量: 673.8
• InChiKey: YKEUOHBRJUALFI-LWPOTHECSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.02
• 重原子数：
  47
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  181
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS
  申请人：Braincells, Inc.

  公开号：EP1991212A1

  公开（公告）日：2008-11-19
• PSYCHO-PHARMACEUTICALS
  申请人：University College Dublin National University Of Ireland, Dublin

  公开号：EP2288345B1

  公开（公告）日：2015-06-10
• DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING
  申请人：Yamauchi Tadakazu

  公开号：US20090233274A1

  公开（公告）日：2009-09-17

  The present invention provides novel target proteins and target genes for drug discovery, and the means that enable the development of novel drugs using the same. More particularly, the present invention provides NCS proteins and genes thereof; screening methods for drug (for example, anti-central nervous disease drug); agents for regulating disease (for example, central nervous disease); production methods of a drug derivative; a complex comprising a drug and NCS protein, and a method of producing the complex; a kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for the determination methods; and the like.
• US8178077B2
  申请人：——

  公开号：US8178077B2

  公开（公告）日：2012-05-15
• [EN] MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS<br/>[FR] MODULATION DE NEUROGENÈSE PAR DES AGENTS NOOTROPES
  申请人：BRAINCELLS INC

  公开号：WO2007104035A1

  公开（公告）日：2007-09-13

  [EN] The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other nootropic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.
  [FR] La présente invention concerne des procédés de traitement de maladies et de conditions pathologiques du système nerveux central et périphérique par la stimulation ou l'accroissement de la neurogenèse. L'invention concerne des compositions et des procédés reposant sur l'utilisation de la mélatonine et d'autre agent nootrope, éventuellement en combinaison avec un ou plusieurs agents neurogènes, pour stimuler ou activer la formation de nouvelles cellules nerveuses.